Indolent Lymphoma

17 clinical trials · Condition

Record	Firm	Date
Low-dose Radiotherapy in iNHL (NCT05543070)	Chinese Academy of Medical Sciences	2022-05-01
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (NCT05003141)	Qilu Puget Sound Biotherapeutics (dba Sound Biologics)	2021-11-15
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (NCT05020678)	Nkarta, Inc.	2021-08-20
Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period (NCT04957693)	Tel-Aviv Sourasky Medical Center	2021-07-05
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT04806035)	TG Therapeutics, Inc.	2021-04-28
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma (NCT04431635)	University of Michigan Rogel Cancer Center	2020-06-15
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (NCT03424603)	Sutro Biopharma, Inc.	2018-02-22
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation (NCT03133221)	University of Maryland, Baltimore	2017-10-23
Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma (NCT03261349)	National Taiwan University Hospital	2017-09-01
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies (NCT01263899)	S*BIO	2010-12-01
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma (NCT00980395)	University of Arizona	2009-07-07
11C-Acetate PET/CT Non-FDG-Avid Tumors (NCT00687778)	Tel-Aviv Sourasky Medical Center	2008-05-01

Track Indolent Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.